DR. FANAROFF:
Based on the previous data of Hendrik and Seidman, one would predict a 6% incidence of hyperbilirubinemia; this study found a 9% incidence rate.
DR. HANSEN: Dr Fanaroff, your original goal seemed to be to identify infants at high risk for severe jaundice, but it appears you were successful in identifying infants at low risk for severe jaundice. Is that a correct interpretation? If so, how does this affect the clinical usefulness of this set of tools?
DR. FANAROFF: That is correct. As we progressed, we found that we were dealing with a negative predictor. As we've already determined, there is a balance between production and elimination of bilirubin, which determines the presence of hyperbilirubinemia. In some cases, although there is increased production, which is measured with the end-tidal carbon monoxide measurement, the ability to excrete it is so good that significant hyperbilirubinemia doesn't develop. I was dealing with a population that was not at risk; there was a 99% predictability using both instruments or 98% just using one.
DR. JAVIER: How many determinations were made for each patient? Did you use a single determination, and did you repeat it again after a few hours? If so, did you notice any difference between the tests? There is a theory that hemolysis is actually a dynamic process.
DR. FANAROFF: For this study, a single test was done. With a large multicenter trial, it's important to keep things as simple as possible. Also, with a multiple study, how do you know how many tests are sufficient? Finally, with multiple tests, there is the possibility of ''cherry picking,'' that is, are you retesting the infants with the best results in previous tests? DR. GARTNER: Did you collect any information on breastfeeding?
DR. FARANOFF: Unfortunately, no. DR. BILL CHAN: Did you collect data on the blood glucuronidase or other factors that might explain the increased serum hyperbilirubin in your study? DR. FANAROFF: We had the blood groupings, and that's not what accounts for it.
DR. DENNERY: Another explanation for the increase in hyperbilirubinemia in this study might be variations in the activity of heme oxygenase. Some preliminary reports out of Japan (Akaba K, Kimura T, Sasaki A, et al.) indicated that in different populations, there may be variations in the level of the gene's ability to function. It would be interesting to look at different polymorphisms within heme oxygenase.
Original Article
& & & & & & & & & & & & & &
DR. STEVENSON:
We have done work with Hajime Nakamura in Kobe, and some infants there have elevations in their production rates, which systematically contribute to part of the problem of a much higher incidence of hyperbilirubinemia. It's possible that there are differences in heme oxygenase expression in the transitional period after birth in the Japanese population, but that's not been studied systematically. We are aware of the differences in conjugation of the curve because of the polymorphisms that impact glucuronidation in that population, but it may be more complicated in the Japanese.
DR DR. YOUNG: When we participated in the Natus study, we changed our management protocol to initiate phototherapy when the level of bilirubin reached 17 mg/dl rather than the previously used standard of 15 mg/dl. This change did not affect patient outcome. We have decreased the use of phototherapy by about 20%. Even more important, we could identify those who are at low risk, and these infants can be safely discharged to return to child health clinics. Infants whose levels are in the intermediate zone are monitored until the bilirubin level declines.
DR. NEM-YUN BOO: The number of G6PD infants in your study was very small. Were you able to determine when they would develop jaundice?
DR. YOUNG: The best tool is still early diagnosis of G6PD deficiency. That's why 20 years ago Hong Kong implemented a program of cord blood screening for G6PD. This program has allowed us to significantly decrease the incidence of jaundice related to G6PD deficiency. Also, educating the parents is of utmost importance.
DR. NEM-YUN BOO: In Malaysia, we also screen infants who have G6PD in cord blood, but they often return a week after discharge with severe jaundice. We still have one or two infants die from kernicterus that develops after discharge.
DR. KAPLAN: This is a major problem. In some infants with a minimal increase in hemolysis, a predischarge bilirubin screening is a good predictor of who of the G6PD-deficient population will develop jaundice. Infants with bilirubin levels under the 50th percentile have a very low risk of developing jaundice; those above the 50th percentile are at high risk. However, this does not resolve the situation that you are describing. These infants are discharged home where they come in contact with some either identifiable or nonidentifiable chemical substance. There is no way to predict that situation before discharge. We have to educate people not to eat fava beans and not to use naphthalene or anything else that we know can be a trigger of hemolysis. But there are so many chemical substances available on the market today, and we don't know which of these substances will trigger hemolysis. The only thing we can do is to warn parents that if the child starts to become jaundiced, they must bring the infant back immediately.
DR. YEUNG: I am aware of a small study indicating that the Greek population was much more jaundiced in Greece, but the migrated population in Australia, even though G6PD deficient, were much less jaundiced during the first week or 10 days. To some extent, this also answers Dr Cashore's question as to why some of the people from Africa moving to North America are less jaundiced. Dr Boo's experience in Kuala Lumpur is exactly what we saw 30 years ago in Hong Kong. Most children were discharged home in good health but returned as late as the end of the fourth week kernicteric because of contamination in the environment. At Chi Yo Hospital, we had a child who suddenly developed severe jaundice with no identifiable reason. Repeated questioning of the mother failed to identify a cause. I asked the mother what sort of tea she was drinking. We found that her mother-in-law was giving her tea that contained chuen-lin, a substance that precipitates active hemolysis. These kinds of substances are often overlooked when we investigate the cause of kernicterus because they are so common.
DR. AHLFORS: Dr Bhutani, one of the things we know about the ability of the infant's albumin to bind bilirubin is that it can change over time. Have you looked at whether some of the infants that cross lines do so not necessarily because they have a load problem, but because they are good binders and they pull a lot of the bilirubin into the vascular space? DR. BHUTANI: That's an area worth investigating. We have focused a lot on the serum bilirubin value, but it's important to identify infants whose serial serum bilirubin levels increase from a lower to a higher risk zone, or tract, because they are a relatively unpredictable group in terms of predicting risk. Measurements of the unbound bilirubin as well as the albumin would be very important. In the first 3 days, when albumin binding is so poor in infants, the infant makes an attempt to maintain a pH of 7.45 by hyperventilation. Healthy infants a mean PCO 2 of about 34 and have a pH of 7.42 to 7.45, which would protect them. There is more to this
Johnson and Chow
Discussion: Prediction of Hyperbilirubinemia issue than just unbound bilirubin. The pH of the infant has a role to play and it requires further investigation. DR. VREMAN: You showed one patient in your study with an ETCO of 0.4 mol/l. I'm concerned about these very low values for ETCO, because infants have a high turnover of red blood cells, and this low level indicates that the survival rate of these red blood cells is unusually high, which is bothersome.
DR. BHUTANI: There was a repeat measurement on this infant a couple of days later, and the ETCO was 1.3 mol/l, still below normal; but there was an increase and the infant had bruising. Whether the low level was related to bruising or whether there was a trigger is not known, but this infant may help us understand the story a bit more.
DR. STEVENSON: If both measurements are accurate, that would mean that the production rates more than doubled, which suggests that something unusual is happening. In most infants, the ETCO normally decreases over time, reflecting the red cell degradation. The pattern of production may be important to consider in the pathology that we see in some of these infants because a lack of a normal decrease, or even a slight increase, would indicate a pathologic process. I would suggest that there may be a conjugation defect that we could identify with genetic testing.
DR. BHUTANI: This infant is certainly a fascinating case that underscores the need for repeat ETCO measurement to assess change. Evaluation must be made before discharge and then at return visits to document change.
DR. CHOWDHURY: Do we know from reliable measurement data that part of the bilirubin that was accumulating was not conjugated? It could be an excretory defect or a storage defect. Could this patient have Rotor's syndrome (Dubin-Johnson syndrome) or even the heterozygous form of that syndrome, which would be important at this age? DR. YOUNG: The level increases by about 30 mol/l every day, so it is a steady rise of the bilirubin level, and then subsequently a drop after day 7. At first the end-tidal CO was normal, and then subsequently (and the bilirubin level is low, around the 40th to 75th percentile) it slowly crosses the percentile to the 75th and then to about the 95th percentile.
DR. CHOWDHURY: The development of MRP2 also takes some time, so the difference would become more and more manifest as time passes. This pattern could easily fit with that if the HPLC, which is a technique which would be able to detect an accumulation of mono and di bilirubin glucuronide and of other bile pigments, showed some accumulation of conjugated bilirubin.
DR. CHOW KIN: You mentioned an infant who had a bilirubin of 8.4 mg/dl on the first day of life. It's important to know exactly when the level was assessed. It if was 48 hours after birth, that level may not be so significant. If it was within 24 hours, then clinically it is quite moderate jaundice already; the level could be predicted to rise as high as 15 mg/dl 24 hours after the first assessment.
DR. BHUTANI: This underscores two points. First, when this infant was discharged he was thought to have jaundice clinically, which triggered further evaluations. Second, the infant was discharged a day after birth, which in many areas would have been considered a second day. So the issue of using bilirubin level as hour specific rather than day specific is important and helps identify whether the level is high, low, or intermediate.
DR. LUI: Dr Young, you reported that about 10% of your normal term infants had serum bilirubin values of more than 15 mg/dl, i.e., values which fall in the higher percentile risk tracts. However, the ETCO levels in these infants were not similarly increased. This would indicate that these babies did not have more bruising and hemorrhage into the tissues, since that would have increased production of carbon monoxide and bilirubin. This suggests that there was a factor, perhaps contributed by the parents, in addition to production of carbon monoxide and bilirubin which contribute to the extent of hyperbilirubinemia seen.
DR. YOUNG: The Phase I study included 151 infants; more were included in later Phase I and Phase II studies. The 10% with serum bilirubin level of more than 15 mg/dl was in a larger population who developed a bilirubin greater than the 95th percentile. This group had a higher ETCO than those below the 95th percentile.
In the detailed analysis of the Phase I study, 16 had developed jaundice and a bilirubin level of more than the 95th percentile. In fact, 5 had a bilirubin level more than the 95th percentile and the rest actually jumped track from the 40th to the 75th percentile. Only a small number jumped track from the 75th to over the 95th percentile over a couple of days.
DR. LUI: They jumped track with no accompanying increase of the ETCO. Why? DR. YOUNG: I would have to review the data, but those infants who were above the 95th percentile had ETCO of more than 2 mol/l. DR. BRATLID: Dr Johnson, in your kernicterus registry, the median bilirubin levels were quite high, but the range was quite wide. In all groups, there were patients with serum bilirubin levels in the low or mid-20s. Can you comment on this?
DR. JOHNSON: This is a graphic illustration of the fact that you sometimes do have to worry about an infant with bilirubin below 25 mg/dl, especially if that level rises rapidly and the infant is still fairly close to delivery and the tumult of changing from inside to outside. This is one reason we believe it's so important to assess bilirubin levels early. All of the infants who were readmitted by day 4 were already at kernicteric levels, but the range of infants who need protection in terms of bilirubin levels is very wide. Most had high levels, but in each group, there were infants who had relatively low levels. If we are going to protect all of these infants, we need to prevent them from developing bilirubin levels in the dangerous ranges, which means treating them at earlier elevated levels.
DR. BRATLID: Dr Bhutani, do you recommend treatment for all infants at the 95th percentile?
DR. BHUTANI: While we were collecting this data from the nomogram, only about half the infants above the 95th percentile track received phototherapy, which was 39% of infants. Those who remained in the 95th percentile track on follow-up eventually got phototherapy, whether 1 day or 12 hours later. I don't think that all infants above the 95th percentile track should get phototherapy, but I think they should be evaluated and considered for phototherapy. DR. JOHNSON: It's important to realize that an infant who came in at day 2 1/2 and had a bilirubin level of 21.5 mg/dl was only 2 1/2 days old. The age at which the infant develops elevated bilirubin also makes a difference in how aggressively the child should be treated.
DR. MAISELS: Dr Johnson, according to your data, an infant can manifest signs of kernicterus with a bilirubin level of 21 mg/dl on day 2. Is that correct? DR. JOHNSON: Yes, the infant you are referring to had severe opisthotonos on day 2.
DR. MAISELS: Was the peak level 21 mg/dl? DR. JOHNSON: The patient was treated at that point. DR. MAISELS: How many infants developed kernicterus who had peak bilirubin levels of less than 30 mg/dl, did not have G6PD deficiency, were not septic, and did not have any other identifiable cause?
DR. JOHNSON: In six of the seven babies with signs of acute stage kernicterus and a readmission serum bilirubin of less than 30 mg/dl, the peak bilirubin could confidently be said to equate with this readmission level. Two of these six had ABO incompatibility with hematocrits of 43 and 42% on days 5 and 6 respectively. Two of the six infants had infection and dehydration, as well as hyperbilirubinemia, on readmission. In one infant, whose readmission hematocrit was 50%, G6PD deficiency was demonstrated before treatment with exchange transfusion. In the remaining infant, readmitted on day 2.5, with ''idiopathic'' jaundice, no risk factors for hyperbilirubinemia were found. DR. BHUTANI: Under present day hospital and physician protocols, routine testing of newborns for ABO incompatibility and possible increased hemolysis is usually not done before hospital, so there is no reason to exclude these infants, because, at readmission, they are found to have increased hemolysis.
Management of infants in the well infant nursery is such that hemolysis is not considered a diagnostic risk factor unless the infant manifests jaundice in the first 24 hours.
DR. MAISELS: I agree that at the time of discharge, there is no diagnosis unless the diagnosis is based on an earlier rise in bilirubin, which does help to make a diagnosis by itself. If there is not an early rise in bilirubin level or if there is one but no one notices it, then it's quite possible that an infant will develop hemolysis and not be detected.
DR. STEVENSON: If you add all the categories together, more than half the infants have some type of hemolytic disease.
DR. JOHNSON: We looked at G6PD deficiency as the immediate cause, but about a third of those infants had infection. Another third had increased hemolysis. Still another group did not appear to have increased hemolysis before discharge, and their hemoglobins were within normal range. In fact, all the infants with G6PD deficiency probably had increases in their hematocrit levels, but they did not exhibit easily detectable gross hemolysis. If you combine the infants with hemolysis and G6PD deficiency with those from ABO or unidentified red blood cell excretion, then hemolysis is an important part of the equation in identifying infants who develop dangerous hyperbilirubinemia. We were concerned about the infants that we couldn't identify before discharge as at risk, which points toward an excretion defect. There must be polymorphisms in the population that makes a big difference. Again, it's only the serum bilirubin level that reflects the balance between production and elimination, as perturbed by the enterohepatic recirculation of bilirubin.
DR. MAISELS: It's important to point out that we don't have a control group for these infants. Neumann is currently studying a group of infants with bilirubin levels greater that 25 ml/dl. To date, they have enrolled 78 infants, none of whom have developed kernicterus. They have now been monitored for 5 years. They undergo detailed neurologic, audiologic, and psychometric evaluations.
DR. JOHNSON: In the past when there was significant Rh hemolytic disease, only 50% of infants with bilirubin levels over 30 ml/dl were reported to have sustained severe damage. Nevertheless, a small number of infants will develop kernicterus. We know that infants can be at risk at those low levels, which is one reason we are trying to find something else that will help us identify why one infant is more vulnerable than another. Unbound bilirubin is not the only factor, but it is a place to start. We need to gear our screening and treatment programs to protect the most vulnerable infant.
DR. MAISELS: I agree. I'm just pointing out that what we need to look at the global picture. There is a group of infants who are clearly being damaged and who could be protected. If they are adequately monitored and there is appropriate intervention, we can eliminate this condition in almost every case.
DR. McDONAGH: Both Dr Fanaroff and Dr Bhutani referred to high performance liquid chromatography (HPLC) measurement of bilirubin concentrations as the ''gold standard.'' I believe we should not use this term in this way. Although HPLC, in principle, is capable of giving more accurate measurements that the Ehrlich's diazo reaction, several HPLC methods are cited in the literature, many of which are not good. There is a problem with standardization of these methods, just as there is with the diazo technique. For example, one of the most widely used methods, the alkaline methanolysis procedure, like other procedures in the literature, doesn't include accounting for the photoisomers, which are invariably present in infants even though they are not getting phototherapy. That procedure is probably not the most accurate when there are high levels of unconjugated bilirubin and you are looking for small amounts of conjugates. There are a variety of HPLC procedures, and they shouldn't be regarded as categorically more accurate than other methods.
DR. BHUTANI: We relied heavily on Gourley's laboratory for our reference standard, so that we have one standard method with an individual well versed in this area. We found that the calibrators themselves were not similar and they changed even within our institution. I agree that there are different HPLC methodologies, but the one that we chose was based on data in the literature.
Discussion: Prediction of Hyperbilirubinemia DR. JOHNSON: And it does detect photoisomers. DR. CASHORE: As we try to help practitioners, several features come to mind. First, the nomogram from Pennsylvania Hospital showed the failure of these percentile levels to decline after day 3 or 4, so that the 30th to 40th through 75th percentiles don't represent what used to be considered the normal distribution. Second, we have lost the art of teaching people how to assess bilirubin levels by age in hours. Our model used to be Rh disease, but since this disease is no longer a problem, we may have stopped either teaching or listening about the assessment of bilirubin by age in hours. Third, we need to encourage visual recognition of early jaundice for those days when the laboratory is closed and the batteries don't work in the skin photometer. When we detect jaundice earlier, we need to ask how many hours old the infant is and whether intervention is required now.
DR. BHUTANI: Yes, and the art needs to be shared with families and nurses, not limited just to pediatricians or family practitioners. Also, with regard to our predictive nomogram, it is unethical to do bilirubin assessment in healthy infants after day 5, which explains why we were limited to show a drop in trajectory.
DR. EBBESEN: At the point when the infants developed kernicterus, their serum bilirubin dropped rapidly. So the levels we see are lower values than the values they would have had just hours before.
